Literature DB >> 16469566

Prognostic value of thrombocytosis in renal cell carcinoma.

Karim Bensalah1, Emmanuelle Leray, Patricia Fergelot, Nathalie Rioux-Leclercq, Jacques Tostain, François Guillé, Jean-Jacques Patard.   

Abstract

PURPOSE: We correlated platelet count to renal tumor characteristics, and evaluated the potential prognostic value of thrombocytosis in localized and metastatic tumors.
MATERIALS AND METHODS: A total of 804 patients operated on for a renal tumor in 2 French centers were included in this study. In all cases TNM stage, Fuhrman grade, tumor size, nodal invasion, ECOG score, histological subtype and platelet count were recorded. Survival estimates were compared with the Kaplan-Meier method and multivariate analysis was performed using a Cox model.
RESULTS: There were 538 (66.9%) males and 266 (33%) females (ratio 2.02) in the patient group. Median age was 62 years. T stages were T1, T2, T3 and T4 in 284 (35.3%), 116 (14.4%), 387 (48.1%) and 17 (2.1%), respectively. There were 112 (13.9%) and 126 (15.7%) patients with nodal and metastatic invasion, respectively. Platelet count was strongly correlated with T stage (p < 0.001), Fuhrman grade (p < 0.001), tumor size (p < 0.001), nodal invasion (p < 0.001) and the presence of distant metastasis (p = 0.01). In univariate analysis all studied factors were significantly predictive of survival (p = 0.0001). Thrombocytosis had an impact on prognosis in localized (p < 0.001) and metastatic (p = 0.003) disease. Several factors were retained in multivariate analysis, namely TNM stage, Fuhrman grade, tumor size, ECOG score and platelet count. In cases with a platelet count of less than 450,000/mm3, the 5-year survival rate was 70%, compared to 38% when the platelet count was 450,000/mm3 or greater.
CONCLUSIONS: Platelet count appears to be an independent prognostic factor in renal cell carcinoma. It reflects a cascade of biological events correlated with tumor aggressiveness. This observation opens new perspectives for exploring carcinogenesis mechanisms and tumor progression in renal cell carcinoma.

Entities:  

Mesh:

Year:  2006        PMID: 16469566     DOI: 10.1016/S0022-5347(05)00526-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  35 in total

1.  Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.

Authors:  David Cella; Joseph C Cappelleri; Andrew Bushmakin; Claudie Charbonneau; Jim Z Li; Sindy T Kim; Isan Chen; M Dror Michaelson; Robert J Motzer
Journal:  J Oncol Pract       Date:  2009-03       Impact factor: 3.840

2.  Prognostic value of thrombocytosis in patients undergoing surgery for colorectal cancer with synchronous liver metastases.

Authors:  C Pedrazzani; G Turri; G Mantovani; C Conti; R Ziello; S Conci; T Campagnaro; A Ruzzenente; A Guglielmi
Journal:  Clin Transl Oncol       Date:  2019-04-02       Impact factor: 3.405

Review 3.  Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Ying Wu; Xiaonan Fu; Xiaoli Zhu; Xuelian He; Chao Zou; Yijie Han; Mingchu Xu; Chengjin Huang; Xin Lu; Yulan Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

4.  Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma.

Authors:  Ismael Domínguez; Stefano Crippa; Sarah P Thayer; Yin P Hung; Cristina R Ferrone; Andrew L Warshaw; Carlos Fernández-Del Castillo
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

5.  Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma.

Authors:  Wassim Kassouf; Robert Siemens; Christopher Morash; Louis Lacombe; Michael Jewett; Larry Goldenberg; Joseph Chin; Michael Chetner; Christopher G Wood; Simon Tanguay; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

6.  Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.

Authors:  Joanna L Sylman; Annachiara Mitrugno; Garth W Tormoen; Todd H Wagner; Parag Mallick; Owen J T McCarty
Journal:  Converg Sci Phys Oncol       Date:  2017-05-17

7.  Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Authors:  Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2018-05-31       Impact factor: 1.862

Review 8.  Paraneoplastic thrombocytosis: the secrets of tumor self-promotion.

Authors:  Richard J Lin; Vahid Afshar-Kharghan; Andrew I Schafer
Journal:  Blood       Date:  2014-05-27       Impact factor: 22.113

9.  Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series.

Authors:  Sabine Brookman-May; Matthias May; Vincenzo Ficarra; Manuela Christine Kainz; Karin Kampel-Kettner; Stephanie Kohlschreiber; Valentina Wenzl; Meike Schneider; Maximilian Burger; Wolf F Wieland; Wolfgang Otto; Derya Tilki; Christian Gilfrich; Markus Hohenfellner; Sascha Pahernik; Thomas F Chromecki; Christian Stief; Richard Zigeuner
Journal:  World J Urol       Date:  2012-08-19       Impact factor: 4.226

10.  Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.

Authors:  Primo N Lara; Catherine M Tangen; Sarah J Conlon; Robert C Flanigan; E David Crawford
Journal:  J Urol       Date:  2008-12-18       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.